Portal de Periódicos da CAPES

Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition

2016; Elsevier BV; Volume: 27; Linguagem: Inglês

10.1016/j.parkreldis.2016.04.016

1873-5126

Giovanni Cossu, Roberto Ceravolo, Maurizio Zibetti, Roberta Arca, Valeria Ricchi, Alessandra Paribello, Daniela Murgia, Aristide Merola, Alberto Romagnolo, Valentina Nicoletti, Giovanni Palermo, Alessandra Mereu, Leonardo Lopiano, Maurizio Melis, Giovanni Abbruzzese, Ubaldo Bonuccelli,

Neurotransmitter Receptor Influence on Behavior

Abstract Objective Our purpose was to determine whether the use of catechol- O -methyltransferase-inhibitors (ICOMT) can reduce the risk of developing levodopa (LD)-induced neuropathy in Parkinson's disease (PD) patients. Methods A multicentre study of 197 PD patients was performed. 144 were exposed to LD for more than three years (LELD group); 53 simultaneously assumed Entacapone for at least eighteen months (LELD_ICOMT group). Results The prevalence of neuropathy in LELD patients was 19.4% whereas it was 5.7% in LELD_ICOMT group with a significant difference (p = 0.025). In LELD_ICOMT cohort the daily LD dose and serum VB12 levels were significantly higher (p < 0.0001), the serum Hcy levels were significantly lower (p = 0.001) compared to LELD group. Conclusion Our results suggest that ICOMT could have a protective effect on the development of LD-induced neuropathy. Their action probably occurs through the metabolic rebalancing of the one-carbon-pathway cycle and is independent of the PD duration and severity and the duration of LD intake.